

To: Minister van VWS[5.1.2e @minvws.nl]
Cc: [5.1.2e | 5.1.2e @modernatx.com]; [5.1.2e 5.1.2e @modernatx.com]
From: [5.1.2e]
Sent: Wed 9/22/2021 12:34:32 PM
Subject: Moderna Milestone: New Clinical Data on COVID-19 Vaccine Moderna
Received: Wed 9/22/2021 12:34:41 PM

Dear Minister de Jonge,

I hope this finds you well.

As previously discussed, Moderna has been working tirelessly to find solutions against the COVID-19 pandemic in the face of existing and emerging variants.

As such, I am delighted to share new clinical data regarding the SpikeVax vaccine's effectiveness concerning the Delta variant and its impact on waning immunity for vaccinated individuals.

First, a prospective cohort study at Kaiser Permanente Southern California showed that our SpikeVax vaccine is highly effective against the Delta variant in a real-world setting. The analysis found our vaccine to have:

- A vaccine efficacy of 87% against COVID-19 diagnosis (99.3% CI: 85-90%)
- A vaccine efficacy of 96% against COVID-19 hospitalization (99.3% CI: 91-98%)

These results are complimented by a recent [vaccine effectiveness study](#) by the U.S. Centers for Disease Control and Prevention (CDC), which showed SpikeVax's efficacy against COVID-19 urgent care or emergency visit was 92% ((95% CI: 89-93%) and against hospitalization was 95% (95% CI: 92-97%) at a median of 96 and 106 days respectively after vaccination.

Second, regarding the impact of waning immunity concerning the Delta variant surge a new analysis of open-label portion of Phase 3 COVE study shows lower risk of breakthrough infection in participants vaccinated more recently (median 8 months after first dose) than participants vaccinated last year (median 13 months after first dose).

These results have been posted to preprint servers and will be submitted for peer-reviewed publication. You can find more details linked [here](#).

We will keep you updated on any further developments.

Kind Regards,

[5.1.2e]
 [5.1.2e Moderna
 mobile : +33 [5.1.2e | e-mail: [5.1.2e @modernatx.com | modernatx.com



Please consider the environment before printing this email

Confidentiality notice and disclaimer: The information in this message and any attachments is intended for the exclusive use of the addressee(s), is confidential and may be privileged or otherwise protected from disclosure. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, of any such information by persons or entities other than the intended addressee(s) is prohibited. If you have received this message in error and are not the intended addressee, please notify the sender immediately and delete this message and any attachments from your system without reading or disclosing them. If you are not the intended addressee, be advised that any use of the information in this message and any attachment is prohibited and may be unlawful, and you must not copy this message or attachment or disclose the contents to any other person.